{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:54:43Z","timestamp":1791179683192,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tuberculosis remains a major global health challenge, with many patients expe- riencing unfavourable treatment outcomes despite standard therapy. Host immune biomarkers, including cytokines, chemokines, and matrix metalloproteinases (MMPs), have shown promise in predicting disease severity and treatment response, but require validation across independent cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We validated previously identified immune biomarkers using baseline plasma samples from a nested case\u2013control cohort within the RePORT India consortium (cases: n=74; controls: n=161). Cytokines (IL-2, IFN-\u03b3, TNF-\u03b1, IL-6, IL-1\u03b2, IL-10, IL-17A, and GM-CSF), chemokines (CCL2, CCL3, CCL4, CXCL1, CXCL8, and CXCL10), and matrix metalloproteinases (MMP-1, MMP-2, MMP-7, and MMP-9) were quantified using multiplex ELISA on the Luminex platform. Statistical analyses included group comparisons, ROC analysis, logistic regression, random forest modelling, princi- pal component analysis, and stability selection to identify optimal biomarker combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated levels of IL-2, IFN-\u03b3, TNF-\u03b1, IL-6, CCL2, CXCL8, CXCL10, MMP-2, MMP-7, and MMP-9 were associated with unfavourable out- comes. IL-2, CXCL8, CCL2, and MMP-2 showed strong individual predictive performance (AUC \u22650.80). Multivariable analysis identified CCL2, CXCL8, and CXCL10 as significant predictors of poor outcomes. A combined biomarker panel comprising CXCL8, MMP-2, and CCL2 demonstrated excellent predictive accu- racy (AUC ~0.90), with sensitivity ranging from 89% to 98% and specificity ranging from 80% to 90%, depending on the biomarker combination and the selected ROC cut-off.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings validate key immune biomarkers and support a multi- marker host biomarker panel for early risk stratification and personalized TB management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1928573","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:33:18Z","timestamp":1791178398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic utility of immune biomarkers for identifying individuals at risk of unfavourable treatment outcomes in pulmonary tuberculosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Agalya","family":"Vanamudhu","sequence":"first","affiliation":[{"name":"Prof. M. Viswanathan Diabetes Research Center","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Prof. M. Viswanathan Diabetes Research Center","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprashath","family":"Mohan","sequence":"additional","affiliation":[{"name":"Prof. M. Viswanathan Diabetes Research Center","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedha","family":"Krishna Rao","sequence":"additional","affiliation":[{"name":"Prof. M. Viswanathan Diabetes Research Center","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"Division of TB Prevention and Elimination Research, ICMR- National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Hissar","sequence":"additional","affiliation":[{"name":"Division of TB Prevention and Elimination Research, ICMR- National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavani","family":"Permal Kannabiran","sequence":"additional","affiliation":[{"name":"Division of TB Prevention and Elimination Research, ICMR- National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash","family":"Babu","sequence":"additional","affiliation":[{"name":"National Institutes of Health-National Institute for Research in Tuberculosis (NIRT)- International Center for Excellence in Research","place":["Chennai, India"]},{"name":"Laboratory of Parasitic Diseases (LPD), of National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardy","family":"Kornfeld","sequence":"additional","affiliation":[{"name":"UMass Chan Medical School","place":["Worcester, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathella","family":"Pavan Kumar","sequence":"additional","affiliation":[{"name":"Division of TB Prevention and Elimination Research, ICMR- National Institute for Research in Tuberculosis","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","unstructured":"Global Tuberculosis Report 2023 [WWW Document]"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70003-7","article-title":"Biomarkers for tuberculosis disease activity, cure, and relapse","volume":"10","author":"Wallis","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0224-2","article-title":"A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis","volume":"24","author":"Imperial","year":"2018","journal-title":"Nat Med"},{"key":"B4","volume-title":"WHO Operational Handbook on Tuberculosis. Module 3: Diagnosis \u2013 Rapid Diagnostics for Tuberculosis Detection (2023 Update)","year":"2023"},{"key":"B5","volume-title":"Bailey & Scott's Diagnostic Microbiology","author":"Forbes","year":"2018"},{"key":"B6","article-title":"An evaluation of symptom and chest radiographic screening in tuberculosis prevalence surveys","volume":"10","author":"den Boon S, White NW, van Lill SW, Borgdorff MW, Verver S, Lombard CJ, et al. (2006). . . 10(8):876\u2013882.","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nri2960","article-title":"Immunological biomarkers of tuberculosis","volume":"11","author":"Walzl","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.chest.2025.05.055","article-title":"Contribution of key comorbidities to unfavorable treatment outcomes among adults with drug-sensitive pulmonary TB in India: A prospective cohort analysis","volume":"169","author":"Sinha","year":"2026","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat Rev Dis Primer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1392256","article-title":"Distinct TB-antigen stimulated cytokine profiles as predictive biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis","volume":"15","author":"Pandiarajan","year":"2024","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00905-2021","article-title":"Baseline IL-6 is a biomarker for unfavourable tuberculosis treatment outcomes: a multisite discovery and validation study","volume":"59","author":"Gupte","year":"2022","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytox.2020.100028","article-title":"Value of serum cytokine biomarkers TNF-\u03b1, IL-4, sIL-2R and IFN-\u03b3 for use in monitoring bacterial load and anti-tuberculosis treatment progress","volume":"2","author":"Nie","year":"2020","journal-title":"Cytokine X"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1104","article-title":"Plasma chemokines are baseline predictors of unfavorable treatment outcomes in pulmonary tuberculosis","volume":"73","author":"Kumar","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2014.09.004","article-title":"Chemokines in tuberculosis: The good, the bad and the ugly","volume":"26","author":"Monin","year":"2014","journal-title":"Semin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4167\/jbv.2020.50.4.203","article-title":"The roles of chemokines in immune response to mycobacterial infection","volume":"50","author":"Paik","year":"2020","journal-title":"J Bacteriol Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.27754","article-title":"Association of plasma matrix metalloproteinase and tissue inhibitors of matrix metalloproteinase levels with adverse treatment outcomes among patients with pulmonary tuberculosis","volume":"3","author":"Kumar","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12879-018-3246-y","article-title":"Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment","volume":"18","author":"Kumar","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00015411","article-title":"Matrix metalloproteinases in tuberculosis","volume":"38","author":"Elkington","year":"2011","journal-title":"Eur Respir J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12649","article-title":"Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis","volume":"52","author":"Sabir","year":"2019","journal-title":"Cell Prolif"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"A prospective blood RNA signature for tuberculosis disease risk","volume":"387","author":"Zak","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/ijmy.ijmy_48_19","article-title":"Immunological host responses as surveillance and prognostic markers in tubercular infections","volume":"8","author":"Waghmare","year":"2019","journal-title":"Int J Mycobacteriology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117605","article-title":"Gender-dependent differences in plasma matrix metalloproteinase-8 elevated in pulmonary tuberculosis","volume":"10","author":"Sathyamoorthy","year":"2015","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1928573\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:33:20Z","timestamp":1791178400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1928573\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1928573"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1928573","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1928573"}}